Diabetes Clinical Trials in Detroit

Showing 421-440 of 526 trials

iDecide.Decido: Diabetes Medication Decision Support Study

NCT01427660

Two of AHRQ 's consumer-focused guides, "Pills for Type 2 Diabetes" and "Premixed Insulin for Type 2 Diabetes" could be of great use to underserved ethnic and racial minority adults. The presentation of content and delivery mechanisms of these Guides, however, needs to be modified to increase their use and impact among these difficult-to-reach populations. To achieve this goal, a long-standing collaboration among African American and Latino community organizations, health care centers and systems, public health organizations, and academics (the REACH Detroit Partnership) is joining with leading experts in the development of personally and culturally tailored health decision aids (University of Michigan's Center for Health Communications Research \[CHCR\] and Center for Behavioral and Decision Sciences in Medicine \[CBDSM\]). The investigators will develop and evaluate a computer tailored online diabetes medication decision aid that will enable community health workers (CHWs) to provide personalized patient education materials to underserved diabetic African American and Latino adults in Detroit, Michigan.

Diabetes, Type 2

University of Michigan190 participantsStarted Sep 2011

Detroit, Michigan, United States

COMPLETEDPhase 3< 1 mile

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.

Diabetes Mellitus, Type 2Acute Coronary Syndrome

Takeda5,380 participantsStarted Sep 2009

Birmingham, Alabama, United States • Dothan, Alabama, United States • Mobile, Alabama, United States +905 more locations

iDecide.Decido: Diabetes Medication Decision Support Study

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Diabetes Trials in Other Cities

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

The CareFUL Prevention Trial

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Dapagliflozin DPPIV Inhibitor add-on Study

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy

Other Conditions in Detroit